New antidote for smoke-related cyanide toxicity shows promise

Smoke inhalation is the major cause of death in fire victims due to cyanide poisoning. However, new research presented at CHEST 2012, the annual meeting of the American College of Chest Physicians, shows that a new antidote, cobinamide, may help reverse the effects of cyanide toxicity.

Researchers from multiple institutions, including the University of California Irvine Medical Center, exposed six ventilator-supported New Zealand white rabbits to cold smoke breaths until toxic carbon monoxide levels were achieved, concurrent with intravenous cyanide infusion.

Intravenous cobinamide was administered in treatment arm animals and compared with control responses.

Results showed that intravenous cobinamide reversed cyanide toxicity in these animals in the face of smoke-induced carbon monoxide exposure, without evident adverse effects.

Researchers concluded that cobinamide shows promise as a potential antidote for in victims and that it could potentially be administered in mass casualty exposure scenarios.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

Rapid response in cases of smoke poisoning

Sep 04, 2012

Smoke poisoning can be caused by a number of things, including cyanides, the salts of hydrocyanic acid. Because the quick diagnosis and treatment of victims with cyanide poisoning is critical and often lifesaving, ...

Recommended for you

Determine patient preferences by means of conjoint analysis

9 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments